By Professor Jason Grebely

Journal articles

Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013

Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004

Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C, 2018, 'Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison', Journal of Viral Hepatitis, 25, pp. 1526 - 1532, http://dx.doi.org/10.1111/jvh.12987

Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011

Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', Lancet Gastroenterology and Hepatology, 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2

Grebely J; Puoti M; Wedemeyer H; Cooper C; Sulkowski MS; Foster GR; Berg T; Villa E; Rodriguez-Perez F; Wyles DL; Schnell G; Alami NN; Zhang Z; Dumas E; Dore GJ, 2018, 'Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials', Open Forum Infectious Diseases, 5, pp. ofy248, http://dx.doi.org/10.1093/ofid/ofy248

Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J, 2018, 'The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat', Journal of Hepatology, 69, pp. 1188 - 1196, http://dx.doi.org/10.1016/j.jhep.2018.06.016

Hickman M; Larney S; Peacock A; Jones H; Grebely J; Degenhardt L, 2018, 'Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?', Addiction, 113, pp. 1768 - 1774, http://dx.doi.org/10.1111/add.14383

Peacock A; Leung J; Larney S; Colledge S; Hickman M; Rehm J; Giovino GA; West R; Hall W; Griffiths P; Ali R; Gowing L; Marsden J; Ferrari AJ; Grebely J; Farrell M; Degenhardt L, 2018, 'Global statistics on alcohol, tobacco and illicit drug use: 2017 status report', Addiction, 113, pp. 1905 - 1926, http://dx.doi.org/10.1111/add.14234

Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917

Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, 20, pp. 621 - 627, http://dx.doi.org/10.1016/j.jmoldx.2018.05.010

Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5

Martinello M; Dore GJ; Matthews GV; Grebely J, 2018, 'Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs', Infectious Disease Clinics of North America, 32, pp. 371 - 393, http://dx.doi.org/10.1016/j.idc.2018.02.003

Cheng ML; Abdel-Hakeem MS; Cousineau SE; Grebely J; Marshall AD; Saeed S; Sagan SM; Shoukry NH; Feld JJ; Macparland SA, 2018, 'The 7th canadian symposium on hepatitis c virus: “toward elimination of hcv: How to get there”', Canadian Liver Journal, 1, pp. 139 - 152, http://dx.doi.org/10.3138/canlivj.2018-0018

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852

Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114

Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ, 2018, 'Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993-2012', BMC Infectious Diseases, 18, http://dx.doi.org/10.1186/s12879-018-3110-0

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837

Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J; Dolan K, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013

Khan S; Bernier A; Dapp D; Fortier E; Krajden M; King A; Grebely J; Sagan SM; Cooper CL; Crawley AM, 2018, '6th canadian symposium on hepatitis C virus: Delivering a cure for hepatitis c infection—what are the remaining gaps?', Canadian Liver Journal, 1, pp. 95 - 105, http://dx.doi.org/10.3138/canlivj.1.2.008

Fortier E; Artenie A; Jutras-Aswad D; Roy É; Grebely J; Bruneau J, 2018, 'A165 SHORT INJECTION CESSATION EPISODES AS OPPORTUNITIES FOR HEPATITIS C PREVENTION', Journal of the Canadian Association of Gastroenterology, 1, pp. 286 - 287, http://dx.doi.org/10.1093/jcag/gwy008.166

Conway B; Dore GJ; Altice F; Litwin A; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C; Gendrano I; Huang H; Chen E; Nguyen B; Wahl J; Barr E; Robertson M; Platt H, 2018, 'A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)', Journal of the Canadian Association of Gastroenterology, 1, pp. 299 - 300, http://dx.doi.org/10.1093/jcag/gwy008.173

Marshall AD; Treloar C; Dore GJ; Grebely J, 2018, 'A239 QUALITATIVE EVALUATION OF THE DECISIONS AND EXPERIENCES OF PEOPLE WHO INJECT DRUGS WHO RECEIVED A LIVER DISEASE ASSESSMENT AS PART OF A LIVER HEALTH PROMOTION CAMPAIGN: THE LIVERLIFE STUDY', Journal of the Canadian Association of Gastroenterology, 1, pp. 419 - 419, http://dx.doi.org/10.1093/jcag/gwy008.240

Shoukry NH; Feld JJ; Grebely J, 2018, 'Hepatitis C: A Canadian perspective', Canadian Liver Journal, 1, pp. 1 - 3, http://dx.doi.org/10.3138/canlivj.1.2.001

Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', Lancet Gastroenterology and Hepatology, 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, 68, pp. 393 - 401, http://dx.doi.org/10.1016/j.jhep.2017.10.019

Høj SB; Minoyan N; Artenie AA; Grebely J; Bruneau J, 2018, 'The role of prevention strategies in achieving HCV elimination in Canada: What are the remaining challenges?', Canadian Liver Journal, 1, pp. 15 - 33, http://dx.doi.org/10.3138/canlivj.1.2.003

Marshall AD; Cunningham EB; Nielsen S; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Seguin-Devaux C; Flisiak R; Foster GR; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancorienė L; Jarcuska P; Kåberg M; Kostrikis LG; Makara M; Maimets M; Marinho RT; Matičič M; Norris S; Ólafsson S; Øvrehus A; Pawlotsky JM; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2018, 'Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe', Lancet Gastroenterology and Hepatology, 3, pp. 125 - 133, http://dx.doi.org/10.1016/S2468-1253(17)30284-4

Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Mir HM; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourlière M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofy001

Jacka B; Bray BC; Applegate TL; Marshall BDL; Lima VD; Hayashi K; DeBeck K; Raghwani J; Harrigan PR; Krajden M; Montaner JSG; Grebely J, 2018, 'Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach', Journal of Viral Hepatitis, 25, pp. 28 - 36, http://dx.doi.org/10.1111/jvh.12758

Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B; Grebely J; Hutchinson SJ, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, 90, pp. 120 - 130, http://dx.doi.org/10.1002/jmv.24919

Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL; Hellard M; Dietze P; Bruneau J; Shoukry NH; Dore GJ; Lloyd AR; Prins M; Page K, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, 66, pp. 20 - 28, http://dx.doi.org/10.1093/cid/cix768

Trickey A; Fraser H; Lim AG; Walker J; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Degenhardt L; Hickman M; May M; Vickerman P, 2018, 'Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study', Journal of Hepatology, 68, pp. S179 - S180, http://dx.doi.org/10.1016/s0168-8278(18)30571-3

Fortier E; Sylvestre M-P; Artenie AA; Justras-Aswad D; Elise R; Grebely J; Bruneau J, 2018, 'One-year injecting frequency trajectories as predictors of hepatitis C acquisition: findings from an observational cohort study of people who inject drugs in Montreal, Canada', JOURNAL OF HEPATOLOGY, 68, pp. S189 - S189, http://dx.doi.org/10.1016/S0168-8278(18)30590-7

Trickey A; Fraser H; Lim AG; Walker J; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Degenhardt L; Hickman M; Vickerman P, 2018, 'The contribution of injecting drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study', Journal of Hepatology, 68, pp. S179 - S179, http://dx.doi.org/10.1016/s0168-8278(18)30570-1

Grebely J; Applegate TL; Cunningham P; Feld JJ, 2017, 'Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis', Expert Review of Molecular Diagnostics, 17, pp. 1109 - 1115, http://dx.doi.org/10.1080/14737159.2017.1400385

Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S; Peacock A, 2017, 'Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review', Lancet Global Health, 5, pp. e1192 - e1207, http://dx.doi.org/10.1016/S2214-109X(17)30375-3

Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L; Peacock A, 2017, 'Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review', Lancet Global Health, 5, pp. e1208 - e1220, http://dx.doi.org/10.1016/S2214-109X(17)30373-X

Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025

Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, 14, pp. 641 - 651, http://dx.doi.org/10.1038/nrgastro.2017.106

Larney S; Hickman M; Guy R; Grebely J; Dore GJ; Gray RT; Day CA; Kimber J; Degenhardt L, 2017, 'Estimating the number of people who inject drugs in Australia', BMC Public Health, 17, pp. 757, http://dx.doi.org/10.1186/s12889-017-4785-7

Marshall AD; Grebely J; Dore GJ; Treloar C, 2017, '‘I didn't want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study', International Journal of Drug Policy, 47, pp. 153 - 160, http://dx.doi.org/10.1016/j.drugpo.2017.06.001

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020

Grebely J; Bruneau J; Bruggmann P; Harris M; Hickman M; Rhodes T; Treloar C, 2017, 'Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy', International Journal of Drug Policy, 47, pp. 26 - 33, http://dx.doi.org/10.1016/j.drugpo.2017.08.001

Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L, 2017, 'Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia', International Journal of Drug Policy, 47, pp. 77 - 85, http://dx.doi.org/10.1016/j.drugpo.2017.05.022

Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002

Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701

Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ, 2017, 'Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs', International Journal of Drug Policy, 47, pp. 51 - 60, http://dx.doi.org/10.1016/j.drugpo.2017.05.019

Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', Lancet Gastroenterology and Hepatology, 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4

Back to profile page